%202.svg)
.webp)
.webp)
.webp)
.webp)
%202%20(1).svg){kind=icon}
Foundayo™ is a prescription medication FDA-approved for chronic weight management in adults with obesity, or adults with overweight and at least one weight-related health condition. Researchers are also studying its use in treating a range of other conditions, including type 2 diabetes.
Foundayo™ belongs to a class of medications called GLP-1 receptor agonists, which work with the body's natural hunger and blood sugar signals to help regulate appetite and support metabolic health.
Unlike injectable GLP-1 medications or peptide-based oral options, orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist.
This means it’s a once-daily pill that can be taken at any time of day, without restrictions on food or water intake. It’s a more convenient option for people who’d rather not use injections or follow guidelines about timing their dose on an empty stomach.
Because of how it works in the body, orforglipron can support meaningful, sustained weight reduction, making it a valuable part of a comprehensive care plan for people managing their weight and related health conditions.Your care team will help determine if it's the right fit, based on your health history, goals, and treatment needs.
.webp)
Foundayo® is a GLP-1 receptor agonist. It mimics GLP-1, a naturally occurring hormone released after you eat that helps regulate blood sugar, appetite, and digestion.
By activating GLP-1 receptors, Foundayo® works to increase insulin secretion when blood sugar is elevated, reduce glucagon (a hormone that raises blood sugar), slow the rate at which food leaves the stomach, and reduce hunger signals in the brain.
By working with these natural hormone signals, the medication helps reduce appetite and increase feelings of fullness, making it easier to eat in alignment with your health goals.
Over time, people using Foundayo® as part of a broader care plan often see meaningful, sustained reductions in body weight.
.png){kind=icon}
for the 0.8 mg dose via Lilly Direct. Foundayo™ is prescribed as part of a personalized medication plan with ongoing support from your knownwell care team. knownwell clinicians will only prescribe medicine that is clinically appropriate.
Foundayo™ can be covered by insurance, but it depends on your plan.
Many commercial plans are expected to include Foundayo™ on their formularies for weight management. Still, coverage will vary by plan, employer, and pharmacy benefit structure.
Also, prior authorization may be required. Plans may ask for documentation of a qualifying diagnosis, BMI, and any previous medications tried.
knownwell helps patients navigate this process. Our dedicated authorization team can assist with prior benefit verification and next steps, so you understand your coverage options before moving forward.
.svg)
.svg%201%20%5BVectorized%5D%20(1).svg)
With insurance, Foundayo® can cost as little as $0.80 per day ($25 per month) for eligible commercially insured patients using the Foundayo® savings card. Actual costs vary based on your plan, benefits, pharmacy, and prescribed dose.
knownwell's care team helps review your coverage and navigate any required approvals, so you understand your options before starting treatment.
If you're paying without insurance, Lilly has announced that self-paying patients will be able to access Foundayo® through LillyDirect's self-pay pharmacy channel, with the lowest dose starting at $149 per month and additional doses costing up to $399 per month.
The company also says that eligible patients enrolled in Medicare Part D may be able to access Foundayo® for $50 per month, beginning as soon as July 1, 2026.
Your knownwell care team will review costs with you as part of your plan.
.png)
.png)
Clinical studies show that Foundayo™ can support meaningful weight reduction over time for many people, when used consistently as part of a broader weight management plan.
The ATTAIN-1 72-week clinical trial enrolled over 3,100 adults with obesity (without diabetes). Participants lost an average of 7.5% of their body weight on the 5.5 mg tablet, 8.4% on the 9 mg tablet, and 11.2% on the 17.2 mg tablet, compared to 2.1% for those who took a placebo. More than half of the participants taking the highest dose achieved at least 10% weight reduction, and more than a third achieved at least 15%.
Orforglipron has also been shown to deliver significant improvements in blood sugar control and weight reduction for adults with type 2 diabetes. In the ACHIEVE-3 head-to-head trial, orforglipron 17.2 mg produced 73.6% greater relative weight loss compared to oral semaglutide 14 mg, alongside meaningfully greater reductions in HbA1c.
Waist circumference decreased by up to ~10 cm (~4 inches), reflecting meaningful reductions in visceral fat.
.png)
%202.png)
Common Foundayo® side effects include nausea, constipation, diarrhea, vomiting, indigestion, stomach discomfort, a headache, swollen belly, fatigue, belching, heartburn, gas, and hair loss, especially when starting or increasing the dose.
These typically improve as your body adjusts. The side effect profile is consistent with those of other GLP-1 receptor agonist medications.
However, Foundayo® can also cause serious side effects, including inflammation of the pancreas, vision problems in people with type 2 diabetes, and severe stomach problems, dehydration, and low blood sugar. Your knownwell care team will discuss these with you before making a recommendation.
Foundayo® isn't appropriate for everyone. Certain medical conditions, a personal or family history of specific thyroid cancers, pancreas or kidney conditions, and certain endocrine disorders can affect eligibility.
Your knownwell care team will review your health history to determine if Foundayo® is a safe option for you.
Foundayo® should be stored at room temperature. The medication is light-sensitive, so it’s a good idea to store the bottle in its carton or a cabinet to protect it from light.
Your knownwell care team will explain the proper storage and handling instructions for your prescription.
Foundayo® is started at a low dose (0.8 mg once daily). The dose is increased gradually over time, typically every 4 weeks, to help the body adjust. The recommended maintenance doses are 2.5 mg, 5.5 mg, 9 mg, and 14.5 mg, with 17.2 mg being the maximum.
Your knownwell care team will review your specific dosing plan and make adjustments based on how your body responds.
%20(1).png)
.png)
.png)
Meet with a knownwell provider to review your options, discuss whether Foundayo™ fits your needs, and get guidance on next steps.
knownwell knows that long-term weight management support is critical. That's why our patients meet with the same clinician throughout their entire time at knownwell.
A closer look at dual incretin biology, peptide engineering, and metabolic effects
Foundayo™ is unlike any GLP-1 medication that came before it. It’s a small-molecule, non-peptide GLP-1 receptor agonist, meaning it activates the same GLP-1 receptor as injectable medications like semaglutide and tirzepatide, but through an entirely different molecular design.
Most GLP-1 medications are peptides. These are short proteins that must be injected because they’d be broken down by stomach acids and digestive enzymes if taken orally.The one peptide-based oral GLP-1 available (oral semaglutide) requires specific dosing conditions: it must be taken on an empty stomach with a small amount of water, followed by a 30-minute fast.
Foundayo™ solves this problem through its non-peptide structure. Because it’s a small molecule rather than a protein, it’s naturally resistant to degradation in the digestive system. This means it can be taken as a once-daily pill at any time of day, with or without food, and without restrictions on water intake.
Foundayo™'s pharmacokinetic profile supports once-daily dosing, providing consistent levels of the medication throughout the day.
This convenience is what distinguishes Foundayo™ from both injectable GLP-1 medications and existing oral peptide-based options. It may expand access to GLP-1 therapy for people who prefer not to use injections or find existing oral dosing requirements difficult to follow.
GLP-1 receptors are expressed in areas of the brain involved in appetite and energy balance, including the hypothalamus and the brainstem.When orforglipron, the active ingredient in Foundayo®, activates these receptors in the brain, it:
This isn’t appetite suppression in the stimulant sense. It's a modulation of the body's own hunger signals, working with the brain's natural regulation systems to help eating feel more naturally controlled.
Foundayo™’s effects extend beyond weight reduction. In clinical trials, treatment with the active ingredient, orforglipron, was associated with improvements in cardiometabolic markers, including:
In the ACHIEVE-3 trial, which included adults with type 2 diabetes, orforglipron also showed clinically meaningful improvements across key cardiovascular risk factors, including non-HDL cholesterol, HDL cholesterol, VLDL cholesterol, total cholesterol, systolic blood pressure, and triglycerides.Among participants in ATTAIN-1 who had prediabetes at the start of the study, up to 83.7% of those taking orforglipron achieved near-normal blood sugar levels, compared with 44.6% of those taking a placebo.
Talk with your provider if you’re pregnant, or if you plan to become pregnant or breastfeed, or if you have a history of:
Talk with your provider if you’re pregnant, or if you plan to become pregnant or breastfeed, or if you have a history of:
.webp)
.png)
.webp)
Get started with weight management care at knownwell.
